vs
Enova International, Inc.（ENVA）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Enova International, Inc.的季度营收约是Revvity的1.1倍（$875.1M vs $772.1M），Revvity净利率更高（12.7% vs 10.4%，领先2.3%），Enova International, Inc.同比增速更快（17.4% vs 5.9%），过去两年Enova International, Inc.的营收复合增速更高（18.0% vs 9.0%）
Enova International是一家全球金融科技企业，提供短期消费贷款、小微企业融资等线上金融服务，主要覆盖北美、南美及欧洲市场，依托先进数据分析技术评估用户信用，为传统金融覆盖不足的群体提供定制化金融产品。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
ENVA vs RVTY — 直观对比
营收规模更大
ENVA
是对方的1.1倍
$772.1M
营收增速更快
ENVA
高出11.5%
5.9%
净利率更高
RVTY
高出2.3%
10.4%
两年增速更快
ENVA
近两年复合增速
9.0%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $875.1M | $772.1M |
| 净利润 | $91.1M | $98.4M |
| 毛利率 | — | — |
| 营业利润率 | 23.7% | 14.5% |
| 净利率 | 10.4% | 12.7% |
| 营收同比 | 17.4% | 5.9% |
| 净利润同比 | 24.9% | 3.9% |
| 每股收益（稀释后） | $3.46 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ENVARVTY
| Q1 26 | $875.1M | — | ||
| Q4 25 | $839.4M | $772.1M | ||
| Q3 25 | $802.7M | $698.9M | ||
| Q2 25 | $764.0M | $720.3M | ||
| Q1 25 | $745.5M | $664.8M | ||
| Q4 24 | $729.6M | $729.4M | ||
| Q3 24 | $689.9M | $684.0M | ||
| Q2 24 | $628.4M | $691.7M |
净利润ENVARVTY
| Q1 26 | $91.1M | — | ||
| Q4 25 | $79.0M | $98.4M | ||
| Q3 25 | $80.3M | $46.7M | ||
| Q2 25 | $76.1M | $53.9M | ||
| Q1 25 | $72.9M | $42.2M | ||
| Q4 24 | $63.7M | $94.6M | ||
| Q3 24 | $43.4M | $94.4M | ||
| Q2 24 | $53.9M | $55.4M |
毛利率ENVARVTY
| Q1 26 | — | — | ||
| Q4 25 | 59.8% | — | ||
| Q3 25 | 57.4% | 53.6% | ||
| Q2 25 | 57.8% | 54.5% | ||
| Q1 25 | 57.2% | 56.5% | ||
| Q4 24 | 56.6% | — | ||
| Q3 24 | 58.0% | 56.3% | ||
| Q2 24 | 58.9% | 55.7% |
营业利润率ENVARVTY
| Q1 26 | 23.7% | — | ||
| Q4 25 | 22.2% | 14.5% | ||
| Q3 25 | 24.5% | 11.7% | ||
| Q2 25 | 24.1% | 12.6% | ||
| Q1 25 | 23.1% | 10.9% | ||
| Q4 24 | 21.3% | 16.3% | ||
| Q3 24 | 22.3% | 14.3% | ||
| Q2 24 | 23.1% | 12.4% |
净利率ENVARVTY
| Q1 26 | 10.4% | — | ||
| Q4 25 | 9.4% | 12.7% | ||
| Q3 25 | 10.0% | 6.7% | ||
| Q2 25 | 10.0% | 7.5% | ||
| Q1 25 | 9.8% | 6.4% | ||
| Q4 24 | 8.7% | 13.0% | ||
| Q3 24 | 6.3% | 13.8% | ||
| Q2 24 | 8.6% | 8.0% |
每股收益（稀释后）ENVARVTY
| Q1 26 | $3.46 | — | ||
| Q4 25 | $2.94 | $0.86 | ||
| Q3 25 | $3.03 | $0.40 | ||
| Q2 25 | $2.86 | $0.46 | ||
| Q1 25 | $2.69 | $0.35 | ||
| Q4 24 | $2.29 | $0.77 | ||
| Q3 24 | $1.57 | $0.77 | ||
| Q2 24 | $1.93 | $0.45 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $96.1M | $919.9M |
| 总债务越低越好 | $4.8B | — |
| 股东权益账面价值 | — | $7.3B |
| 总资产 | $6.9B | $12.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ENVARVTY
| Q1 26 | $96.1M | — | ||
| Q4 25 | $71.7M | $919.9M | ||
| Q3 25 | $53.6M | $931.4M | ||
| Q2 25 | $55.6M | $991.8M | ||
| Q1 25 | $55.5M | $1.1B | ||
| Q4 24 | $73.9M | $1.2B | ||
| Q3 24 | $67.5M | $1.2B | ||
| Q2 24 | $60.1M | $2.0B |
总债务ENVARVTY
| Q1 26 | $4.8B | — | ||
| Q4 25 | $4.5B | — | ||
| Q3 25 | $4.1B | — | ||
| Q2 25 | $4.0B | — | ||
| Q1 25 | $3.8B | — | ||
| Q4 24 | $3.6B | — | ||
| Q3 24 | $3.3B | — | ||
| Q2 24 | $3.2B | — |
股东权益ENVARVTY
| Q1 26 | — | — | ||
| Q4 25 | $1.3B | $7.3B | ||
| Q3 25 | $1.3B | $7.4B | ||
| Q2 25 | $1.2B | $7.6B | ||
| Q1 25 | $1.2B | $7.6B | ||
| Q4 24 | $1.2B | $7.7B | ||
| Q3 24 | $1.2B | $7.9B | ||
| Q2 24 | $1.1B | $7.9B |
总资产ENVARVTY
| Q1 26 | $6.9B | — | ||
| Q4 25 | $6.5B | $12.2B | ||
| Q3 25 | $6.0B | $12.1B | ||
| Q2 25 | $5.7B | $12.4B | ||
| Q1 25 | $5.5B | $12.4B | ||
| Q4 24 | $5.3B | $12.4B | ||
| Q3 24 | $5.0B | $12.8B | ||
| Q2 24 | $4.8B | $13.4B |
负债/权益比ENVARVTY
| Q1 26 | — | — | ||
| Q4 25 | 3.37× | — | ||
| Q3 25 | 3.20× | — | ||
| Q2 25 | 3.23× | — | ||
| Q1 25 | 3.14× | — | ||
| Q4 24 | 2.98× | — | ||
| Q3 24 | 2.79× | — | ||
| Q2 24 | 2.78× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $182.0M |
| 自由现金流经营现金流 - 资本支出 | — | $161.8M |
| 自由现金流率自由现金流/营收 | — | 21.0% |
| 资本支出强度资本支出/营收 | — | 2.6% |
| 现金转化率经营现金流/净利润 | — | 1.85× |
| 过去12个月自由现金流最近4个季度 | — | $509.4M |
8季度趋势，按日历期对齐
经营现金流ENVARVTY
| Q1 26 | — | — | ||
| Q4 25 | $498.8M | $182.0M | ||
| Q3 25 | $481.8M | $138.5M | ||
| Q2 25 | $447.4M | $134.3M | ||
| Q1 25 | $391.1M | $128.2M | ||
| Q4 24 | $430.5M | $174.2M | ||
| Q3 24 | $398.6M | $147.9M | ||
| Q2 24 | $360.9M | $158.6M |
自由现金流ENVARVTY
| Q1 26 | — | — | ||
| Q4 25 | $487.1M | $161.8M | ||
| Q3 25 | $470.5M | $120.0M | ||
| Q2 25 | $436.1M | $115.5M | ||
| Q1 25 | $378.3M | $112.2M | ||
| Q4 24 | $420.3M | $149.8M | ||
| Q3 24 | $387.6M | $125.6M | ||
| Q2 24 | $349.9M | $136.6M |
自由现金流率ENVARVTY
| Q1 26 | — | — | ||
| Q4 25 | 58.0% | 21.0% | ||
| Q3 25 | 58.6% | 17.2% | ||
| Q2 25 | 57.1% | 16.0% | ||
| Q1 25 | 50.7% | 16.9% | ||
| Q4 24 | 57.6% | 20.5% | ||
| Q3 24 | 56.2% | 18.4% | ||
| Q2 24 | 55.7% | 19.7% |
资本支出强度ENVARVTY
| Q1 26 | — | — | ||
| Q4 25 | 1.4% | 2.6% | ||
| Q3 25 | 1.4% | 2.6% | ||
| Q2 25 | 1.5% | 2.6% | ||
| Q1 25 | 1.7% | 2.4% | ||
| Q4 24 | 1.4% | 3.4% | ||
| Q3 24 | 1.6% | 3.3% | ||
| Q2 24 | 1.8% | 3.2% |
现金转化率ENVARVTY
| Q1 26 | — | — | ||
| Q4 25 | 6.32× | 1.85× | ||
| Q3 25 | 6.00× | 2.97× | ||
| Q2 25 | 5.87× | 2.49× | ||
| Q1 25 | 5.36× | 3.03× | ||
| Q4 24 | 6.76× | 1.84× | ||
| Q3 24 | 9.18× | 1.57× | ||
| Q2 24 | 6.70× | 2.87× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ENVA
暂无分部数据
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
